Common use of Time for Exercise Clause in Contracts

Time for Exercise. (a) Allergan may exercise the License Option with respect to any ASTI Product on a country-by-country basis at any time during the period beginning on the date hereof and ending (i) with respect to the Unitxx Xxxxxx, 00 xxxs after clearance by the FDA to market such ASTI Product in the United States, and (ii) with respect to any other country, 90 days after the earlier of (A) clearance by the appropriate regulatory agency to market such ASTI Product in such country and (B) clearance by the FDA to market such ASTI Product in the United States. Notwithstanding the foregoing, the License Option shall expire, to the extent not previously exercised, at the close of business on the 30th day after the expiration of the Purchase Option or, with respect to a particular ASTI Product, upon exercise by Allergan of the global buy-out option for such ASTI Product under the License Agreement for such ASTI Product. In any case, Allergan must exercise the License Option for a particular ASTI Product in a particular country prior to the first commercial sale of such product in such country by Allergan or any of its Affiliates, sublicensees, distributors or marketing partners.

Time for Exercise. (a) Allergan ALZA may exercise the License Option with respect to any ASTI Product on a country-by-country basis at any time during the period beginning on the date hereof and ending (i) with respect to the Unitxx XxxxxxUnited States, 00 xxxs 30 days after clearance by the FDA to market such ASTI XXX xx xxxxxx xxxh Crescendo Product in the United States, and (ii) with respect to any other country, 90 days after the earlier of (A) clearance by the appropriate regulatory agency to market such ASTI Crescendo Product in such country and (B) clearance by the FDA to market such ASTI Crescendo Product in the United States. Notwithstanding the foregoing, the License Option shall expire, to the extent not previously exercised, at the close of business on the 30th day after the expiration of the Purchase Option or, with respect to a particular ASTI Crescendo Product, upon exercise by Allergan ALZA of the global buy-out option for such ASTI Crescendo Product under the License Agreement for such ASTI Crescendo Product. In any case, Allergan ALZA must exercise the License Option for a particular ASTI Crescendo Product in a particular country prior to the first commercial sale of such product in such country by Allergan ALZA or any of its Affiliates, sublicensees, distributors or marketing partners.

Time for Exercise. (a) Allergan may exercise the License Option with respect to any ASTI Product on a country-by-country basis at any time during the period beginning on the date hereof and ending (i) with respect to the Unitxx Xxxxxx, 00 xxxs after clearance by the FDA to market such ASTI Product in the United States, and (ii) with respect to any other country, 90 days after the earlier of (A) clearance by the appropriate regulatory agency to market such ASTI Product in such country and (B) clearance by the FDA to market such ASTI Product in the United States. Notwithstanding the foregoing, the License Option shall expire, to the extent not previously exercised, at the close of business on the 30th day after the expiration of the Purchase Option or, with respect to a particular ASTI Product, upon exercise by Allergan of the global buy-out option for such ASTI Product under the License Agreement for such ASTI Product. In any case, Allergan must exercise the License Option for a particular ASTI Product in a particular country prior to the first commercial sale of such product in such country by Allergan or any of its Affiliates, sublicensees, distributors or marketing partners.country

Time for Exercise. (aA) Allergan may exercise the License Option with respect to any ASTI Product on a country-by-country basis at any time during the period beginning on the date hereof and ending (i) with respect to the Unitxx Xxxxxx, 00 xxxs after clearance by the FDA to market such ASTI Product in the United States, and (ii) with respect to any other country, 90 days after the earlier of (A) clearance by the appropriate regulatory agency to market such ASTI Product in such country and (B) clearance by the FDA to market such ASTI Product in the United States. Notwithstanding the foregoing, the License Option shall expire, to the extent not previously exercised, at the close of business on the 30th day after the expiration of the Purchase Option or, with respect to a particular ASTI Product, upon exercise by Allergan of the global buy-out option for such ASTI Product under the License Agreement for such ASTI Product. In any case, Allergan must exercise the License Option for a particular ASTI Product in a particular country prior to the first commercial sale of such product in such country by Allergan or any of its Affiliates, sublicensees, distributors or marketing partners.country